Literature DB >> 32623702

Danlou Tablet Improves Chronic Intermittent Hypoxia-Induced Dyslipidemia and Arteriosclerosis by HIF-1α-Angptl4 mRNA Signaling Pathway.

Jing-Jing Tang1, Guang-Xi Li1,2, Zhi-Guo Liu1, Rong Yi1, Dong Yu3, Yue-Bo Zhang4, Shuang-Qiao Zhao5, Shi-Han Wang6,7.   

Abstract

OBJECTIVE: To detect whether Danlou Tablet (DLT) regulates the hypoxia-induced factor (HIF)-1α-angiopoietin-like 4 (Angptl4) mRNA signaling pathway and explore the role of DLT in treating chronic intermittent hypoxia (CIH)-induced dyslipidemia and arteriosclerosis.
METHODS: The mature adipocytes were obtained from 3T3-L1 cell culturation and allocated into 8 groups including control groups (Groups 1 and 5, 0.1 mL of cell culture grade water); DLT groups (Groups 2 and 6, 0.1 mL of 1,000 µg/mL DLT submicron powder solution); dimethyloxalylglycine (DMOG) groups (Groups 3 and 7, DMOG and 0.1 mL of cell culture grade water); DMOG plus DLT groups (Groups 4 and 8, DMOG and 0.1 mL of 1,000 µg/mL DLT submicron powder solution). Groups 1-4 used mature adipocytes and groups 5-8 used HIF-1 α-siRNA lentivirus-transfected mature adipocytes. After 24-h treatment, real-time polymerase chain reaction and Western blot were employed to determine the mRNA and protein expression levels of HIF-1 α and Angptl4. In animal experiments, the CIH model in ApoE-/- mice was established. Sixteen mice were complete randomly divided into 4 groups including sham group, CIH model group [intermittent hypoxia and normal saline (2 mL/time) gavage once a day]; Angptl4 Ab group [intermittent hypoxia and Angptl4 antibody (30 mg/kg) intraperitoneally injected every week]; DLT group [intermittent hypoxia and DLT (250 mg/kg) once a day], 4 mice in each group. After 4-week treatment, enzyme linked immunosorbent assay was used to detect the expression levels of serum total cholesterol (TC) and triglyceride (TG). Hematoxylin-eosin and CD68 staining were used to observe the morphological properties of arterial plaques.
RESULTS: Angptl4 expression was dependent on HIF-1 α, with a reduction in mRNA expression and no response in protein level to DMOG or DLT treatment in relation to siHIF-1 α -transfected cells. DLT inhibited HIF-1 α and Angptl4 mRNA expression (P<0.05 or P<0.01) and reduced HIF-1 α and Angptl4 protein expressions with DMOG in mature adipocytes (all P<0.01), as the effect on HIF-1 α protein also existed in the presence of siHIF-1 α (P<0.01). ApoE-/- mice treated with CIH had increased TG and TC levels (all P<0.01) and atherosclerotic plaque. Angptl4 antibody and DLT both reduce TG and TC levels (all P<0.01), as well as reducing atherosclerotic plaque areas, narrowing arterial wall thickness and alleviating atherosclerotic lesion symptoms to some extent.
CONCLUSION: DLT had positive effects in improving dyslipidemia and arteriosclerosis by inhibiting Angptl4 protein level through HIF-1 α-Angptl4 mRNA signaling pathway.
© 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chinese medicine; Danlou Tablet; angiopoietin-like 4; arteriosclerosis; dyslipidemia; hypoxia-induced factor

Mesh:

Substances:

Year:  2020        PMID: 32623702     DOI: 10.1007/s11655-020-3255-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  42 in total

1.  Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis.

Authors:  Richard C Li; Bodduluri Haribabu; Steven P Mathis; Jinkwan Kim; David Gozal
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

Review 2.  Obstructive sleep apnea: an emerging risk factor for atherosclerosis.

Authors:  Luciano F Drager; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho
Journal:  Chest       Date:  2011-08       Impact factor: 9.410

3.  Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice.

Authors:  Claire Arnaud; Laureline Poulain; Patrick Lévy; Maurice Dematteis
Journal:  Atherosclerosis       Date:  2011-08-31       Impact factor: 5.162

4.  Efficacy of continuous positive airway pressure treatment in treating obstructive sleep apnea hypopnea syndrome associated with carotid arteriosclerosis.

Authors:  Yong-Qian Jiang; Jin-Shan Xue; Juan Xu; Zhi-Xiang Zhou; You-Lin Ji
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

5.  Early signs of atherosclerosis in obstructive sleep apnea.

Authors:  Luciano F Drager; Luiz A Bortolotto; Maria Cecília Lorenzi; Adelaide C Figueiredo; Eduardo M Krieger; Geraldo Lorenzi-Filho
Journal:  Am J Respir Crit Care Med       Date:  2005-05-18       Impact factor: 21.405

6.  The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition.

Authors:  Claire Arnaud; Pauline C Beguin; Sylvie Lantuejoul; Jean-Louis Pepin; Christiane Guillermet; Graziano Pelli; Fabienne Burger; Vanessa Buatois; Christophe Ribuot; Jean-Philippe Baguet; François Mach; Patrick Levy; Maurice Dematteis
Journal:  Am J Respir Crit Care Med       Date:  2011-06-16       Impact factor: 21.405

7.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea.

Authors:  Luciano F Drager; Jianguo Li; Mi-Kyung Shin; Christian Reinke; Neil R Aggarwal; Jonathan C Jun; Shannon Bevans-Fonti; Carole Sztalryd; Sheila M O'Byrne; Olessia Kroupa; Gunilla Olivecrona; William S Blaner; Vsevolod Y Polotsky
Journal:  Eur Heart J       Date:  2011-04-09       Impact factor: 29.983

9.  Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial.

Authors:  Craig L Phillips; Brendon J Yee; Nathaniel S Marshall; Peter Y Liu; David R Sullivan; Ronald R Grunstein
Journal:  Am J Respir Crit Care Med       Date:  2011-04-28       Impact factor: 21.405

10.  Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Jonathan Jun; Christian Reinke; Djahida Bedja; Dan Berkowitz; Shannon Bevans-Fonti; Jianguo Li; Lili A Barouch; Kathleen Gabrielson; Vsevolod Y Polotsky
Journal:  Atherosclerosis       Date:  2009-10-17       Impact factor: 5.162

View more
  2 in total

1.  PPARγ Mediates the Cardioprotective Roles of Danlou Tablet After Acute Myocardial Ischemia-Reperfusion Injury.

Authors:  Meng Wei; Mengying Guo; Xinxiu Meng; Lin Li; Hongyun Wang; Mingxue Zhang; Yihua Bei
Journal:  Front Cardiovasc Med       Date:  2022-03-25

2.  Butyric acid alleviated chronic intermittent hypoxia-induced lipid formation and inflammation through up-regulating HuR expression and inactivating AMPK pathways.

Authors:  MiaoShang Su; Yifan He; Sichen Xue; Jueke Yu; Xikai Ren; Nan Huang; Rukkaiya Abdullahi; Manhuan Xu
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.